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Muscle-specific overexpression 
of AdipoR1 or AdipoR2 gives rise 
to common and discrete local 
effects whilst AdipoR2 promotes 
additional systemic effects
Sahar Keshvari1, Darren C. Henstridge2, Choaping Ng1, Mark A. Febbraio2,3 & 
Jonathan P. Whitehead1
Hypoadiponectinemia and adiponectin resistance are implicated in the aetiology of obesity-related 
cardiometabolic disorders, hence represent a potential therapeutic axis. Here we characterised the 
effects of in vivo electrotransfer-mediated overexpression of the adiponectin receptors, AdipoR1 
or AdipoR2, into tibialis anterior muscle (TAM) of lean or obese mice. In lean mice, TAM-specific 
overexpression of AdipoR1 (TAMR1) or AdipoR2 (TAMR2) increased phosphorylation of AMPK, AKT and 
ERK and expression of the insulin responsive glucose transporter glut4. In contrast, only TAMR2 increased 
pparα and a target gene acox1. These effects were decreased in obese mice despite no reduction in 
circulating adiponectin levels. TAMR2 also increased expression of adipoQ in TAM of lean and obese mice. 
Furthermore, in obese mice TAMR2 promoted systemic effects including; decreased weight gain; reduced 
epididymal fat mass and inflammation; increased epididymal adipoQ expression; increased circulating 
adiponectin. Collectively, these results demonstrate that AdipoR1 and AdipoR2 exhibit overlapping and 
distinct effects in skeletal muscle consistent with enhanced adiponectin sensitivity but these appear 
insufficient to ameliorate established obesity-induced adiponectin resistance. We also identify systemic 
effects upon TAMR2 in obese mice and postulate these are mediated by altered myokine production. 
Further studies are warranted to investigate this possibility which may reveal novel therapeutic 
approaches.
Adiponectin is a key adipokine that displays a variety of beneficial effects to reduce diabetes, atherosclerosis and 
cardiometabolic disease1. Adiponectin regulates carbohydrate and lipid metabolism, reducing hepatic glucose 
production and enhancing fatty acid oxidation in skeletal muscle1. In contrast to most other adipokines, circulat-
ing adiponectin levels are typically reduced in obesity, type 2 diabetes and associated conditions1. Moreover, mice 
lacking adiponectin or humans with polymorphisms that compromise adiponectin production develop metabolic 
dysfunction and or type 2 diabetes2. Hence, therapeutic strategies to reverse hypoadiponectinaemia are attractive. 
Increasing evidence indicates that adiponectin resistance also contributes to the development of metabolic and 
cardiovascular diseases3–11. While the molecular mechanisms that give rise to adiponectin resistance are poorly 
defined strategies to overcome adiponectin resistance are also of therapeutic potential.
The beneficial effects of adiponectin are mediated primarily via the action of two atypical 
seven-transmembrane domain (7TMD) receptors, AdipoR1 and AdipoR212. These receptors are structurally and 
functionally distinct from other 7TMD receptors, having intracellular N-termini and extracellular C-termini, 
and couple adiponectin to a range of downstream effectors including AMPK, PPARα , AKT and ERK by mech-
anisms that are incompletely understood12–15. Molecular and cellular studies have revealed differences between 
AdipoR1 and AdipoR2 that include different binding properties12, cell surface expression16–18 and temporal 
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signaling profiles19,20. Furthermore, investigations in mice have demonstrated contrasting expression profiles, 
with AdipoR1 expressed relatively ubiquitously compared with AdipoR212, and activation of alternate signaling 
pathways21. For example, studies in knockout mice indicate that in liver activation of AMPK is mediated primar-
ily by AdipoR1 whilst PPARα appears to be downstream of AdipoR221.
In the current study we aimed to extend our cell-based investigations demonstrating differences between 
AdipoR1 and AdipoR217,20 to compare the effects of overexpression of either AdipoR1 or AdipoR2 in skele-
tal muscle in lean and obese mice. Overexpression was achieved by in vivo electrotransfer (IVE) of the tibia-
lis anterior muscle (TAM) that allowed characterization of local, TAM-specific changes in phosphorylation of 
downstream signaling effectors and expression of genes involved in glucose and lipid metabolism as well as deter-
mination of somewhat unexpected systemic effects in response to overexpression of AdipoR2.
Results
Overexpression of AdipoR2 in TAM of obese mice has unexpected systemic effects. Using in 
vitro, cell-based systems we previously demonstrated that acute treatment with globular adiponectin resulted in 
different temporal signaling profiles in cells overexpressing AdipoR1 or AdipoR2, with the former promoting 
relatively acute activation (peaking at 15 min) and the latter more chronic activation (peaking after 24 h) respec-
tively20. In the present study we have employed in vivo electrotransfer (IVE) to extend these observations and 
determine the effects of short-term (14 day) overexpression of AdipoR1 and AdipoR2 in mouse tibialis anterior 
muscle (TAM) of lean (chow fed) and obese mice fed a high fat diet (HFD) for 8 weeks.
IVE is a powerful experimental approach that allows manipulation of the gene of interest in the test leg and 
comparison with the control leg in the same animal22,23. Here, we first used IVE to introduce a plasmid encod-
ing GFP into the right TAM (test) and empty plasmid into the left TAM (control) of 16 week old lean or obese 
C57BL/6 mice. After 14 days mice were sacrificed and GFP expression was examined visually and by qRT-PCR. 
Visual inspection (under standard laboratory lighting) revealed robust GFP expression throughout the entire 
target muscle and none in neighbouring muscles or in the control leg in the same animal (Fig. 1a and b). GFP 
expression in the test TAM, but not the control TAM, was also confirmed by qRT-PCR (Fig. 1c).
Having confirmed the efficacy and specificity of the IVE protocol we then went on to perform experiments to 
characterise the effects of TAM-specific overexpression of AdipoR1 (TAMR1) or AdipoR2 (TAMR2) in lean (average 
body weight 29.85 g) and obese mice (average body weight 40.75 g). Following IVE of AdipoR1 or AdipoR2 into 
the test TAM and empty plasmid into the control TAM mice were maintained on chow or HFD for a further 14 
days then sacrificed for analysis. To our surprise in obese mice TAMR2 resulted in significantly reduced weight 
gain and elevated circulating adiponectin levels compared with TAMR1 obese mice (weight gain: − 0.6 ± 0.3 vs 
1.3 ± 0.3 g, p = 0.001; adiponectin: 3.0 ± 0.3 vs 1.8 ± 0.2 μ g/ml, p < 0.01; n = 6/group).
HFD induced obesity does not alter AdipoR1 or AdipoR2 expression in TAM. The effects on weight 
gain and circulating adiponectin levels were not anticipated and prompted us to redesign the study to include lean 
and obese control (sham) groups that were transduced with empty plasmid in both the left and right TAMs in par-
allel to the AdipoR1 or AdipoR2 transduced mice to allow direct comparison across groups. The extent of TAMR1 
or TAMR2 was determined 14 days post IVE. Expression of both endogenous and exogenous genes was determined 
using primers specific for either mouse or human receptors respectively. The expression of endogenous receptors 
was unaffected by either IVE or diet (Fig. 2a and b), with adipoR1 expressed at levels 10-fold higher than adipoR2. 
Human AdipoR1 and AdipoR2 were only detected in the test TAM and were expressed at similar levels in lean 
and obese mice (Fig. 2c and d). Western blot analysis was performed to characterise overexpression at the protein 
level. Western blot using HA-antibody confirmed expression of the exogenous HA-tagged proteins in only the 
test TAM and demonstrated that AdipoR1 and AdipoR2 proteins were expressed at similar levels in lean and 
obese mice (Fig. 2e and f). Western blot with a validated AdipoR2 antibody (that recognises both human and 
mouse AdipoR224) revealed a 2-fold increase in total AdipoR2 in TAM from the test leg compared to the control 
leg. Unfortunately we were unable to perform a similar analysis of AdipoR1 protein due to the lack of a suita-
ble, validated antibody that recognised both human and mouse AdipoR1 efficiently. Nevertheless, these results 
demonstrated the success and efficiency of the IVE approach and also showed that expression of the endogenous 
or exogenous receptors was not affected by HFD-induced obesity.
TAMR1 or TAMR2 promotes activation of proximal signaling events and these effects are reduced 
in HFD-induced obesity. We next sought to examine the local effects of TAMR1 or TAMR2 at the level of prox-
imal phosphorylation events using ELISA or Alphascreen technology. Phosphorylation of AMPK was increased 
around 2-fold in response to overexpression of either receptor in TAM of lean mice (Fig. 3a). Overexpression 
of either receptor also significantly increased AMPK phosphorylation in obese mice however the magnitude of 
this effect was less than that observed in lean mice. Similar results were seen for AKT phosphorylation. TAMR1 or 
TAMR2 increased AKT phosphorylation in TAM by around 50%, whilst the magnitude of this effect was reduced 
by around 20% in obese mice (Fig. 3b). In lean mice, phosphorylation of ERK was increased 3-fold by TAMR1 and 
2-fold by TAMR2 (Fig. 3c). The magnitude of these effects was reduced by 55% and 45% in obese mice such that 
overexpression of AdipoR1 or AdipoR2 no-longer resulted in a significant increase in test verses control TAM 
(Fig. 3c). These changes occurred in the absence of any change in the total levels of AMPK, AKT and ERK pro-
teins (Supplementary Fig. S1). These results show that, at least under these experimental conditions, overexpres-
sion of AdipoR1 or AdipoR2 have similar effects on proximal signaling effectors and also suggest the development 
of HFD-obesity induced adiponectin resistance.
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TAMR2, but not TAMR1, promotes increased expression of genes involved in lipid metabolism 
and these effects are reduced in HFD-induced obesity. We then investigated the effects of overex-
pression of the receptors on expression of key genes involved in glucose and lipid metabolism in skeletal muscle. 
Overexpression of AdipoR1 or AdipoR2 resulted in a 2-fold increase in expression of the insulin-responsive 
glucose transporter glut4 in lean mice but this effect was not observed in obese mice (Fig. 4a). In contrast to the 
effects described above that were common to both AdipoR1 and AdipoR2, only the latter effected changes in 
genes involved in lipid metabolism, pparα and a downstream target gene acox1. Indeed, in lean but not obese 
TAMR2 mice pparα and acox1 (encoding acyl-CoA oxidase) were both increased around 2-fold (Fig. 4b and c). 
It has previously been reported that adiponectin and AdipoR1 promote increased expression of PPARα coacti-
vator 1α (PGC1α ) and mitochondrial biogenesis25. Therefore, we also examined the effects of overexpression of 
the receptors on expression of pgc1α as well as genes encoding the mitochondrial uncoupling proteins UCP2 
and UCP3. However, TAMR1 and TAMR2 had no effect on the expression of these genes in lean or obese mice 
(Supplementary Fig. S2). These results demonstrate different effects on local gene expression following TAMR1 or 
TAMR2 and also provide further evidence of adiponectin resistance in the face of HFD-induced obesity.
TAMR2, but not TAMR1, promotes increased expression of adipoQ in TAM from lean and obese mice. 
Next, we examined expression of adipoQ (encoding adiponectin) in test and control TAM. As expected, expres-
sion of adipoQ was relatively low in control muscle from lean mice (1000-fold less than in epididymal fat). Obesity 
increased adipoQ expression 2.2-fold (n = 18/group; p = 0.001), consistent with previous reports26, whilst TAMR2 
increased adipoQ levels 6–7 fold in TAM from both lean and obese mice respectively (Fig. 4d).
Figure 1. IVE-mediated expression of GFP. GFP protein expression in (a) test and (b) control (empty vector) 
TAM at the time of tissue collection. (c) qRT-PCR analysis showing GFP expression in test (T) verses control 
(C) TAM in lean and obese mice. Data are expressed as mean ± SEM; n = 3 in each group; *p < 0.05.
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TAMR2 in obese mice reduces HFD-induced weight gain, adipose tissue mass and inflammation, 
and increases circulating adiponectin levels. Consistent with the findings in our pilot study (see above) 
we again observed a significant decrease in weight gain in TAMR2 obese mice compared with obese control mice 
(transduced with empty plasmid in both legs) or TAMR1 obese mice (Fig. 5a). The latter also promoted a modest but 
significant reduction in weight gain compared with the obese control group (Fig. 5a and Supplementary Fig. S3). 
To address this further we measured epididymal and subcutaneous fat pad weights. Consistent with the reduced 
weight gain, fat pad weights were also significantly reduced in the TAMR2 obese mice (Fig. 5b and c). In light of 
these surprising observations we performed qRT-PCR on the epididymal and subcutaneous fat pads (and liver) 
using primers specific for human AdipoR2 to rule out the possibility that these effects may reflect leaky expression 
of AdipoR2 in tissues other than the test TAM. In all cases we were unable to detect human AdipoR2 expression 
(data not shown) leaving us to conclude that these effects are most likely mediated indirectly via the increased 
expression of AdipoR2 in TAM. Having established this, we performed further characterisation of the epididymal 
fat pads aiming to define the impact on the inflammatory signature. As expected, HFD-induced obesity resulted 
in a significant increase in expression of inflammatory markers including the pro-inflammatory cytokine TNFα 27, 
the chemokine monocyte chemoattractant protein (MCP)− 128, the monocyte/macrophage markers CD11b, 
CD11c, CD68, and F4/8029 (Fig. 6a–f). TAMR1 or TAMR2 had no effect on inflammatory gene expression in lean 
mice. However, in TAMR2 obese mice there was a significant reduction in the expression of all inflammatory 
Figure 2. Characterisation of IVE-mediated overexpression of AdipoR1 and AdipoR2. qRT-PCR analysis 
of expression levels of endogenous mouse (a) adipoR1 and (b) adipoR2 and exogenous human (c) R1-HA and 
(d) R2-HA expression in left vs right TAM of control (sham) and test (T) vs control (C) TAM of TAMR1 (R1) and 
TAMR2 (R2) mice. Data are expressed as mean ± SEM; n = 6 in each group; ****p < 0.0001. (e) Representative 
western blot of HSP (membrane fractions) of TAM lysates derived from TAMR1 mice probed with HA antibody 
(top panel) and NaK ATPase antibody (lower panel). (f) Representative western blot of HSP (membrane 
fractions) of TAM lysates derived from TAMR2 mice probed with HA antibody (top panel), in-house R2 antibody 
(middle panel) and NaK ATPase antibody (lower panel); n = 3 in each group of lean and obese mice.
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markers, such that expression levels were comparable to those in lean mice (Fig. 6a–f). Moreover, TAMR1 obese 
mice presented an intermediate profile with significant reductions in mcp1, cd11b, cd11c, cd68 and f4/80 com-
pared with obese sham mice (Fig. 6a–f). We also determined the effects of diet and gene transduction on adipoQ 
expression. All groups showed similar expression except for the TAMR2 obese mice, where adipoQ expression 
was significantly elevated (Fig. 6g). To investigate this further we measured circulating adiponectin, glucose and 
insulin levels. Consistent with the gene expression, and our pilot study, circulating adiponectin levels were signif-
icantly increased in TAMR2 obese mice (Fig. 7a). Random glucose levels were unaffected by either overexpression 
of AdipoR1 and AdipoR2 or HFD-induced obesity (Fig. 7b). In contrast, serum insulin levels were markedly 
elevated in HFD-induced obesity in sham or TAMR1 obese mice (Fig. 7c). This effect was reversed in TAMR2 obese 
mice (Fig. 7c).
We performed a similar analysis of the subcutaneous adipose tissue which revealed a more modest inflam-
matory response in the face of HFD-induced obesity and no effect of TAMR1 or TAMR2 (Fig. 8a–f). Surprisingly, 
adipoQ expression was significantly increased by obesity in this depot (Fig. 8g).
Collectively, these results suggest that TAM-specific overexpression of AdipoR2, and to a lesser extent 
AdipoR1, results in reduced HFD-induced weight gain concomitant with amelioration of HFD-induced adipose 
inflammation in epididymal fat pads, increased adiponectin expression and circulating adiponectin levels as well 
as reduced hyperinsulinemia.
Discussion
In the current study we aimed to extend molecular and cellular studies by comparing the effects of overexpression 
of AdipoR1 or AdipoR2 in skeletal muscle in lean and obese mice. We employed IVE to mediate overexpression 
of AdipoR1 or AdipoR2 in TAM of lean or HFD-induced obese mice. In lean mice TAM-specific overexpression 
of either receptor resulted in increased phosphorylation of downstream effectors and elevated expression of the 
insulin responsive glucose transporter glut4. In contrast, only overexpression of AdipoR2 resulted in increased 
Figure 3. TAMR1 or TAMR2 results in increased phosphorylation of downstream signalling effectors.  
(a) Quantitation of AMPK phosphorylation in TAM lysates from lean and obese control (sham), TAMR1 (R1) 
and TAMR2 (R2) mice determined by ELISA. Quantitation of (b) AKT and (c) ERK phosphorylation in TAM 
lysates from sham, R1 and R2 mice determined by Alphascreen. Data are expressed as mean ± SEM; n = 6 in 
each group; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001; significant difference of test (T) vs control (C) 
TAM in lean or obese mice.
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expression of pparα and the target gene acox1. In obese mice the magnitude of all of these effects was reduced 
even though receptor expression and circulating adiponectin levels were maintained or increased. Surprisingly, 
TAMR2 in obese mice resulted in a significant decrease in weight gain, adipose tissue mass and inflammation and 
a significant increase in circulating adiponectin levels. Collectively, these results identify overlapping effects of 
AdipoR1 and AdipoR2 as well as additional, distinct effects of the latter that provide a foundation for further 
investigations aimed at reducing obesity-related complications.
Investigations at the molecular and cellular level have provided clear evidence that AdipoR1 and AdipoR2 
display different properties in terms of adiponectin binding12, cell surface expression, oligomerization and sign-
aling17,19,20,30. Consistent with this scenario, whole animal studies, predominantly involving characterization of 
AdipoR1 or AdipoR2 knockout mice, have demonstrated different signaling outputs, such as coupling of hepatic 
AMPK and PPARα activity to AdipoR1 and AdipoR2 respectively21, and phenotypic consequences following 
deletion of either receptor21,31–33. Whilst informative, there are caveats to this loss of function approach given 
Figure 4. TAMR1 or TAMR2 increase glut4 expression but only the latter increases the expression of 
adipoQ and genes involved in lipid metabolism. qRT-PCR analysis of (a) glut4, (b) pparα, (c) acox1 (d) and 
adipoQ expression in lean and obese control (sham), TAMR1 (R1) and TAMR2 (R2) mice. Data are expressed as 
mean ± SEM; n = 6 in each group; *p < 0.05, **p < 0.01, ****p < 0.0001; significant difference of test (T) vs 
control (C) TAM in lean or obese mice.
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oligomerization of AdipoR1 and AdipoR212,19,34 has been shown to alter properties of the receptor complex and 
downstream signaling outputs17,19. For example, our observations that under physiological conditions (no serum 
withdrawal) cell surface expression of AdipoR2 is limited unless it is co-expressed with AdipoR117 has clear impli-
cations when considering the impact of AdipoR1 deletion, which is also likely to compromise AdipoR2 function. 
Furthermore, adiponectin receptor interacting proteins such as ERp46 have been shown to modulate receptor 
oligomerization, cell surface expression and downstream signaling24. Thus, a gain of function approach may be 
expected to provide important complementary information. Typically such studies have tended to focus on the 
effects of overexpression of either AdipoR1 or AdipoR2. For example, overexpression of AdipoR1 in rat skeletal 
muscle was reported to improve insulin sensitivity23 whilst overexpression of AdipoR2 in liver increased PPARα 
and protected against progression of NASH35. To the best of our knowledge there are no examples where such 
studies have compared the effects of overexpression of AdipoR1 or AdipoR2 in skeletal muscle in vivo.
Skeletal muscle is a recognized target of adiponectin action, with adiponectin increasing fatty acid oxidation 
and glucose uptake and enhancing insulin sensitivity by activation of pathways involving AMPK and PPARα 1,26,36. 
In addition, numerous studies have provided evidence of adiponectin resistance in skeletal muscle from 
rodents5,7,8,37 and humans3,4,9. Whilst muscle-specific deletion of AdipoR1 has established a key role for AdipoR125 
this does not preclude a role for AdipoR2 in mediating the beneficial effects of adiponectin in skeletal muscle or 
the potential of AdipoR2-based therapies. Thus, in the current study we used IVE to compare the effects of over-
expression of AdipoR1 or AdipoR2 in TAM of lean or HFD-induced obese mice.
Figure 5. TAMR2 reduces weight gain and fat pad weight in obese mice. Graphs showing (a) average weight 
gain and (b) epididymal and (c) subcutaneous fat pad weights in lean and obese control (sham), TAMR1 (R1) 
and TAMR2 (R2) mice two weeks post IVE. Data are expressed as mean ± SEM; n = 6 in each group; *p < 0.05, 
**p < 0.01, ****p < 0.0001; significant difference vs control (sham) obese mice.
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Neither IVE nor HFD-induced obesity affected expression of endogenous receptors at the mRNA level and 
endogenous adipoR1 was expressed around 10-fold higher than adipoR2, consistent with a previous report12. 
Measurement of both gene and protein (HA) indicated that the exogenous human receptors were expressed at 
similar levels, with IVE increasing total AdipoR2 levels in TAM by around 100%. Unfortunately we were una-
ble to determine the impact of AdipoR1 overexpression on total levels due to the lack of a suitable antibody. 
Nevertheless, similar levels of overexpression of AdipoR1 and AdipoR2 in TAM of lean mice resulted in compa-
rable elevation of phosphorylation events including AMPK, AKT and ERK as well as increased glut4 expression 
Figure 6. TAMR2 reduces HFD-induced inflammation and increases adipoQ expression in epididymal fat 
pads of obese mice. qRT-PCR analysis of (a) tnfα, (b) mcp1, (c) cd11b, (d) cd11c, (e) cd68, (f) f4/80 and  
(g) adipoQ expression in epididymal fat pads from lean and obese control (sham), TAMR1 (R1) and TAMR2 
(R2) mice. Data are presented as mean ± SEM; n = 6 in each group; *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001; significant difference vs control (sham) obese mice. #p < 0.05, ##p < 0.01, ###p < 0.001, 
####p < 0.0001; significant difference between lean and obese mice within genotype (sham, R1 or R2).
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suggesting that, at least under these conditions, they mediate similar effects consistent with enhanced adiponectin 
and insulin sensitivity. Furthermore, these beneficial effects were reduced in the context of HFD-induced obesity 
by 20–60%. Given circulating adiponectin levels were not decreased these findings are consistent with the devel-
opment of adiponectin resistance, at a level distal to receptor expression.
Only overexpression of AdipoR2 resulted in increased expression of pparα and acox1. This is consistent with 
the findings of impaired hepatic PPARα activity in AdipoR2 knockout mice21 but contrasts with observations in 
endothelial cells, where overexpression of either AdipoR1 or AdipoR2 was sufficient to mediate PPARα activa-
tion38. Once again, these effects were blunted in obesity providing further evidence of adiponectin resistance.
Emerging evidence suggests adiponectin is produced by skeletal muscle and that this is increased in response 
to obesity or inflammation26,39,40. Consistent with these observations, we observed a 2-fold increase in adipoQ lev-
els in TAM from obese mice. Intriguingly, overexpression of AdipoR2 promoted increased expression of adipoQ 
in both lean and obese mice. The molecular basis for this effect is unclear, particularly given that all other local 
effects of TAMR2 were diminished in obese mice. Further investigations are warranted to elaborate the underlying 
mechanisms, which may reveal novel strategies to induce adiponectin expression more globally.
Perhaps the most surprising observations in this study relate to the effects of TAMR2 reducing weight gain in 
obese mice. Indeed, weight gain in HFD-fed obese mice transduced with AdipoR2 was indistinguishable from 
Figure 7. TAMR2 increases circulating adiponectin levels and normalises insulin levels in obese mice. 
Serum levels of (a) total adiponectin, (b) glucose and (c) insulin in non-fasted control (sham), TAMR1 (R1) and 
TAMR2 (R2) lean and obese mice. Data are presented as mean ± SEM; n = 6 in each group; *p < 0.05, **p < 0.01; 
significant difference vs control (sham) obese mice. ####p < 0.0001; significant difference between lean and obese 
mice within genotype (sham, R1 or R2).
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that in the lean, chow-fed mice. This effect was also reflected by a modest but significant reduction in epididymal 
and subcutaneous fat pad weights, compared with those from obese sham or TAMR1 mice, and a striking reso-
lution of adipose tissue inflammation in the epididymal fat pad. Moreover, adipoQ expression was significantly 
elevated in the epididymal fat pad from the obese TAMR2 mice as were circulating levels of adiponectin. It is 
noteworthy that these observations (reduced weight gain and elevated adiponectin) are consistent across two 
independent studies, performed in two distinct research facilities, using different sets of reagents with differ-
ent mouse cohorts. Whilst unexpected, evidence from the literature supports the notion that overexpression of 
Figure 8. TAMR1 or TAMR2 do not affect inflammation in subcutaneous fat pad. qRT-PCR analysis of (a) tnfa, 
(b) mcp1, (c) cd11b, (d) cd11c, (e) cd68, (e) f4/80 and (g) adipoQ expression in subcutaneous fat pads from lean 
and obese control (sham), TAMR1 (R1) and TAMR2 (R2) mice. Data are presented as mean ± SEM; n = 6 in each 
group; #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001; significant difference between lean and obese mice 
within genotype (sham, R1 or R2).
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either AdipoR1 or AdipoR2 may prevent weight gain. Hydrodynamic delivery of AdipoR2 to the liver resulted in 
reduced diet-induced weight gain and adipose tissue mass41 whilst global or macrophage-specific overexpression 
of AdipoR1 were also sufficient to reduce diet-induced weight gain42,43. Whilst it remains possible that the IVE 
approach employed in the current study may have resulted in transduction of cells other than the TAM we were 
unable to detect evidence of such leaky expression in epididymal or subcutaneous fat pads or in liver. Thus, we 
propose that overexpression of AdipoR2 in skeletal muscle results in altered expression of a circulating factor, 
possibly a myokine in a manner similar to that detailed for adipoQ, and that this underpins the reduced weight 
gain and associated improvements. It also remains possible that the observed changes may be due, at least in part, 
to alterations in locomotor activity. Clearly, further studies are required to investigate this intriguing hypothesis.
In summary, we have demonstrated that overexpression of AdipoR1 or AdipoR2 in mouse skeletal mus-
cle promote similar effects at the level of proximal signaling events and glut4 expression whilst only AdipoR2 
promotes activation of the PPARα axis. All of these effects were blunted in the face of obesity, consistent with 
the development of adiponectin resistance at the level of skeletal muscle. Finally, muscle-specific overexpres-
sion of AdipoR2 gave rise to several unexpected local and systemic effects that included increased expression 
of adipoQ in muscle and epididymal adipose as well as increased circulating levels of adiponectin, and reduced 
HFD-induced weight gain, adipose tissue mass and inflammation, and reduced hyperinsulinemia. However, these 
effects appeared unable to ameliorate muscle adiponectin resistance. Future studies, investigating the effects of 
more global muscle-specific overexpression of AdipoR2 may provide further insights into the underlying mecha-
nisms which may provide novel strategies to reverse hypoadiponectinemia and or adiponectin resistance.
Materials and Methods
Animals. All experimental procedures were carried out in accordance with approved protocols by the Alfred 
Medical Research Education Precinct (AMREP) Animal Ethics Committee or the University of Queensland 
Animal Ethics Unit and were conducted using the Guidelines of the National Health and Medical Research 
Council. Male WT C57Bl/6 mice (AMREP AS, Melbourne, VIC, Australia or University of Queensland Biological 
Resource, Brisbane, QLD, Australia) were used for all experiments and commenced when mice were 8 weeks 
of age. Animals were maintained at 22.0 ± 0.5 °C under a 12-h day, 12-h night cycle and fed standard chow diet 
containing 5% of total energy from fat. At 8 weeks of age, animals were divided into two groups. Half kept on 
standard chow diet and the rest were fed high fat diet containing 43% of total calories from fat (lard) (Specialty 
Feeds, Glen Forrest, WA, Australia) for 8 weeks before in vivo electrotransfer.
Reagents and antibodies. Reagents were from Sigma–Aldrich (Castle Hill, Australia) unless otherwise 
stated. Primary antibodies against HA and Sodium Potassium ATPase were from Covance (Washington, USA) 
and Abcam (Melbourne, Australia) respectively. Primary antibodies against AMPK, AKT and ERK were from 
Cell-Signaling technology (Danvers, Massachusetts). ‘In-house’ AdipoR2 antibody has been described previ-
ously24. Secondary antibodies were from Life Technology (Invitrogen).
Molecular biology. Original constructs encoding C-terminally epitope-tagged (HA) human AdipoR1 and 
AdipoR2 were as described24. Plasmid DNA was prepared using a Plasmid Purification Gigaprep kit (Qiagen, 
Valencia, CA, USA) according to the manufacturer’s specifications. The DNA concentration was quantified using 
a Nanodrop ND-1000 Spectrophotometer (Biolab, Scoresby, VIC, Australia) and the DNA dissolved in saline 
(154 mmol/l NaCl) to a final concentration of 4 μ g/μ l.
In vivo electrotransfer (IVE). IVE was performed as described22. Briefly, mice were anaesthetised with 
isoflurane, their hind limbs were shaved and TA muscles were injected with 30 μ l of 0.5 U/μ l hyaluronidase. Two 
hours later mice were again anaesthetised with isoflurane and 100 μ g empty vector, GFP, HA-tagged AdipoR1 or 
HA-tagged AdipoR2 (in 25 μ l saline) was injected into the right TA muscle. The left TA muscle was injected with 
25 μ l empty vector. Stainless steel electrodes attached to an ECM-830 electroporator (BTX, Holliston, MA) were 
placed on the muscle and square-wave electrical pulses (200 V/cm) were applied eight times with an electrical 
pulse generator at a rate of 1 pulse/s, with each pulse being of 20 ms duration. Two weeks later muscles and other 
tissues were dissected, snap frozen in liquid nitrogen and stored at − 80 °C.
Real-time PCR. Gene expression levels were quantified using real-time PCR assay. Mice TAMs were pow-
dered under liquid nitrogen and homogenized using Fast prep-24 (MP Biomedicals, NSW, Australia) in Trizol 
(Invitrogen, Australia). Epididymal and subcutaneous adipose tissue and liver were homogenized as above. 
Total RNA was then extracted as per the manufacturer’s instructions and resuspended in nuclease-free water. 
Genomic DNA contamination of RNA preparations was eliminated by digestion with DNase I amplification 
grade (Invitrogen, Australia). cDNA was synthesized from 1 μg total RNA using cDNA synthesis kit (Bioline, 
NSW, Australia) and RT-PCR was performed using the SYBR Hi-ROX kit (Bioline) on a 7900HT Fast Real-time 
PCR system (Ambion Life Technologies). Results are quoted to the mRNA level compared to TATA box, the 
expression of which was unchanged by the treatments. Primer sequences are listed in Supplementary Table S1.
Western blot. Mice TAMs were powdered under liquid nitrogen and homogenized using Fast prep-24 (MP 
Biomedicals, NSW, Australia) in lysis buffer. Lysates were depleted of nuclei via centrifugation at 800 g for 10 min. 
The supernatant was then centrifuged at 257,000 g for 1 h, and the pellet (HSP containing membrane) was resus-
pended in lysis buffer and protein concentration was determined by bicinchononic acid (BCA) assay (Pierce) 
using BSA as the standard. 60 μ g protein was then loaded and resolved by SDS-PAGE on polyacrylamide gels, 
transferred to membranes and blocked with 5% BSA. The immunoreactive proteins were detected with enhanced 
chemiluminescence after incubation with appropriate primary and secondary antibodies.
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Measurement of circulating adiponectin, glucose and insulin levels. All analyses were made on 
serum taken from non-fasted animals and were performed in accordance with the manufacturer’s instructions. 
Total circulating adiponectin was measured using an adiponectin ELISA (R&D Systems, Minneapolis, MN, 
USA). Blood glucose was measured using a glucose colorimetric assay kit (Cayman chemical, Michigan, USA). 
Insulin levels were measured using a mouse insulin ELISA (Mercodia, Uppsala, Sweden).
AMPK phosphorylation ELISA. TAMs were powdered under liquid nitrogen and homogenized using 
Fast prep-24 (MP Biomedicals, NSW, Australia) in lysis buffer. Phosphorylation of AMPK in TA muscle was 
measured using a PathScan Phospho-AMPKα (Thr172) Sandwich ELISA (Cell-Signaling technology, Danvers, 
Massachusetts) according to the manufacturer’s instruction.
Akt and ERK phosphorylation assays. Alphascreen analysis was performed as previously described20. 
TAMs were powdered under liquid nitrogen and homogenized using Fast prep-24 (MP Biomedicals, NSW, 
Australia) in Alphascreen lysis buffer. Phosphorylation of Akt and ERK was measured using AlphaScreen 
SureFire kits essentially as described (PerkinElmer Life and Analytical Sciences, Waltham, MA, USA). Plates 
were read using a POLARstar Omega plate reader.
Statistical analysis. Data are presented as mean ± SEM. Significance was determined using paired t test to 
compare control and test TAM and two-way ANOVA followed by Tukey’s multiple comparison test with statisti-
cal significance defined as p < 0.05.
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